On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
FridayDec 03, 2021 12:28 pm

Q1 Diagnostic Coverage & Reimbursement Conference, Boston

Date: December 6-7, 2021 Venue: Boston, MA Reimbursement executives attempt to comply with stringent commercial and public payer standards as the diagnostic industry evolves and expands into ever more specialized areas of testing. Provisions and specific evidence required to ensure coverage are always evolving, but the technology appears to be progressing even faster, posing unique hurdles in showing product value and integrating innovative diagnostics into existing payment schemes. The Diagnostic Coverage & Reimbursement conference has brought together more than 1200 industry professionals over the last ten years to discuss crucial challenges affecting diagnostic technology pricing, allowing the industry to better…

Continue Reading

FridayDec 03, 2021 9:30 am

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Announces Research and Technology Progress, Offers Corporate Update

Investment banking firm The Maxim Group reiterates ‘buy’ rating on MCURF following the company’s updates on pivotal research and technology, including The Desire Project, manufacturing of synthetic ibogaine, and the iSTRYM platform MINDCURE is focused on developing psychedelic compounds to scale science-backed and evidentiary-based mental health therapy worldwide In July, MINDCURE filed for patents on two routes of full chemical synthesis, which initiated the production of Good Laboratory Practice (“GLP”) ibogaine, which will lead to the production of Good Manufacturing Practice (“GMP”) ibogaine to scale and manufacture a global supply of its synthetic ibogaine In addition to this pre-clinical trial,…

Continue Reading

FridayDec 03, 2021 9:30 am

NCIA’s 7th Annual Cannabis Business Summit & Expo Launches BLOOM: A Brands Experience

The NCIA will host the 7th Annual Cannabis Business Summit & Expo on December 15-17, 2021, in San Francisco This year’s event will feature BLOOM: A Brands Experience, designed to provide attendees with the ability to see, touch, and smell a variety of cannabis products on the expo floor In addition to Bloom, the conference will also feature two unique offsite tours, including a visit to the Dark Heart Nursery, as well as a unique cannabis-infused San Francisco city cruise NCIA’s 7th Annual Cannabis Business Summit & Expo takes place at San Francisco’s Moscone Center from December 15-17, 2021. Hosted…

Continue Reading

FridayDec 03, 2021 9:30 am

FingerMotion Inc. (FNGR) Reports on November 22 Annual Meeting Results

FingerMotion released results from the annual meeting held on November 22, 2021 It announced the re-appointment of executive officers and its Board of Directors It also reported on the appointment of an independent accounting firm FingerMotion (OTCQX: FNGR) held its annual meeting of stockholders on November 22, 2021. Among the issues covered included the election of specific figures into the company’s Board of Directors, coupled with the approval of the FNGR 2021 stock incentive plan and executive compensation. The company just announced that various matters were duly ratified and have since been implemented by its Board. They included: The election…

Continue Reading

FridayDec 03, 2021 9:00 am

Flora Growth Corp. (NASDAQ: FLGC) Enters Cannabis Beverages Market, Extends Portfolio of Luxury Products with Tonino Lamborghini Licensing Agreement

Flora Growth recently entered into a licensing agreement to produce and distribute Tonino Lamborghini-branded cannabis beverages across North America and Colombia, with an initial focus on the U.S. market The company will produce the product line using molecular tagging and authentication technology that will guarantee product verification and allay concerns of counterfeit products Through the licensing agreement, Flora has entered into the cannabis beverages market amid increasing demand for CBD-based products The recent agreement follows a November 15 announcement that FLGC had completed the acquisition of Vessel Brand Inc., an industry leader in luxury cannabis consumer technology Internationally focused cannabis…

Continue Reading

FridayDec 03, 2021 9:00 am

StraightUp Resources Inc. (CSE: ST) (OTCQB: STUPF) Marks the Successful Completion of its 2021 Ferdinand Gold Project Exploration Plan With the Discovery of Multiple Targets

Groundwork exploration kicked off in August, led by Orix Geosciences The survey revealed multiple areas of high merit and potential mineralization This complements a sediment sampling conducted back in 2001 by the Ontario Geological Survey With these results, StraightUp can now execute its right to acquire 100% interest in the property In early 2021, StraightUp Resources (CSE: ST) (OTCQB: STUPF) acquired an option to purchase the Ferdinand Gold Property in Ontario and set out to explore the property for potential mineralization (https://ibn.fm/o1XoL). Groundwork exploration kicked off in the month of August, spearheaded by Orix Geosciences. On November 29, 2021, the…

Continue Reading

FridayDec 03, 2021 9:00 am

PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF), The Digital Face of the Plant-Based Community

PlantX seeks to redefine the plant-based community through e-commerce, content sharing, and community-building efforts With over 5,000 plant-based products, the company also promises to be the one-stop-shop for everything plant-based It is leveraging the internet and technology to bring its products and services closer to customers By doing so, it is laying down the standard operating procedures for achieving success as a plant-based e-commerce enterprise As of 2019, the plant-based food and beverage market in North America was valued at $14.08 billion (https://ibn.fm/XehMr). Globally, it is projected that by 2027, this industry will be valued at $74.2 billion, representing a…

Continue Reading

ThursdayDec 02, 2021 9:30 am

Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Expands POC Health Lab Testing to Include Kidney Function Marker

Avricore Health is a point of care pharmacy services developer that is providing lab-quality testing for select health conditions at pharmacies in Canada Avricore’s trademarked HealthTab(TM) platform networks patients, pharmaceutical professionals and other medical providers with a patient-privacy respecting solution that helps patients monitor their conditions at local community stores without the necessity of busy doctors’ offices scheduling In addition to the kidney-function monitoring solution announced just recently, HealthTab is currently outfitted to provide lab results for evaluating diabetes, heart disease, COVID, RSV, and other viral exposures Avricore’s pilot HealthTab rollout includes sites in eastern Canada’s Ontario province and western…

Continue Reading

ThursdayDec 02, 2021 9:30 am

Nemaura Medical Inc. (NASDAQ: NMRD) Releases Q2-2021 Results, Signs Global Commercial Contract with MySugarWatch DuoPack Limited

NMRD releases fiscal Q2-2021 results, provides business update Highlights include pending revenue recognition, global commercial contract with MySugarWatch DuoPack Limited, appointment of Dr. Osama Hamdy to advisory board Company operates at intersection of $59 billion Type 2 diabetes market, $50+ billion pre-diabetic market, $60 billion wearable weight loss and wellness applications sector  Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, recently released its fiscal Q2-2021 results and provided a business update (https://ibn.fm/TX286). Financial highlights from the announcement included $26.8M cash on hand, and receipt of…

Continue Reading

ThursdayDec 02, 2021 9:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Touts Highlights of ‘Transformative’ Second-Quarter Performance

Report notes significant and swift advancements in company R&D pipeline and overall business Preliminary data indicates CYB003 may provide significant treatment benefits that address limitations of oral psilocybin CYBN programs and new psychedelic chemical entities have potential to transform treatment landscape for various psychiatric and neurological conditions Q2 2021 has been a transformative quarter for Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics(TM). The company released its financial and operational report for the period recently, with notable company milestones and achievements highlighted (https://ibn.fm/ucAed). “The first half of the year has been a transformative period…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered